DNA Diagnostics Market to Almost Double by 2022 with 14.3% CAGR

October 04, 2017

WELLESLEY, Mass., Oct 04, 2017 – The discovery of new biomarkers for patient screening and development of simpler and cheaper molecular diagnostic tests is driving double-digit growth in the global molecular diagnostics market. BCC Research projects the market to reach $23.8 billion in 2022 from $12.2 billion in 2017, thanks to a 14.3% CAGR led by big demand for microassays.

Molecular Diagnostics: Technologies and Global Marketsreports that molecular diagnostics and molecular imaging for diagnostics are benefiting greatly from research since the completion of the Human Genome Project. Biomarkers are playing increasingly important roles, especially in the cancer disease area. Within the market for DNA diagnostics, the report identifies three major types of clinical assays or tests: microarray and lab-on-a-chip (LAOC, or biochip) diagnostics, polymerase chain reaction (PCR)-based diagnostic assays and in situ hybridization (ISH) assays.

Microarrays will lead in terms of market size and projected growth. Currently, the major clinical application of DNA microarrays is not yet gene expression profiling, but rather still the examination of a patient’s DNA sequence, increasingly the whole genome. Screening for oncology and infectious diseases will remain the primary applications for microarrays. These products, which demonstrated combined sales of $3.7 billion in 2016, should push the global microarray market toward $13.1 billion by 2022 at a 20.1% CAGR.

Research Highlights

•  PCR sales, which totaled more than $4 billion in 2016, will grow at a 9.7% CAGR to reach $7.2 billion by 2022.
• Microarray sales are expected to exceed PCR for the first time in 2017.
• Diagnostic assays that allow rapid screening (high-throughput or miniaturized setups) are attractive to users and clinicians, driving demand for these tests.

“The molecular diagnostics market continues to emphasize user-friendly diagnostics that perform well on core platforms,” says BCC Research analyst Jon Evans, who authored the report.

Nine companies control more than 75% of the molecular diagnostics market. Roche alone commands about 30% of the market, with molecular diagnostic tests for oncology, virology, microbiology and blood screening. Other key players include Roche Diagnostics, Qiagen NV, Gen-Prob, Abbott Diagnostics, Becton Dickinson and Siemens.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.

Molecular Diagnostics: Technologies and Global Markets( BIO063D )
Publish Date: Sep 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.